Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

Trial Profile

A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2018

At a glance

  • Drugs Cefepime/tazobactam (Primary) ; Ciprofloxacin; Meropenem
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Wockhardt
  • Most Recent Events

    • 03 Oct 2018 Planned initiation date changed from 25 Aug 2018 to 25 Dec 2018.
    • 21 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top